Connection
Petter Bjornstad to Dipeptidyl-Peptidase IV Inhibitors
This is a "connection" page, showing publications Petter Bjornstad has written about Dipeptidyl-Peptidase IV Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.257 |
|
|
|
-
Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI. The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. Endocr Rev. 2020 04 01; 41(2).
Score: 0.163
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 Jul; 27(7):3943-3956.
Score: 0.058
-
Le?n Jim?nez D, Cherney DZI, Bjornstad P, Castilla-Guerra L, Miramontes Gonz?lez JP. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am J Physiol Renal Physiol. 2018 11 01; 315(5):F1406-F1415.
Score: 0.036